{"id":"https://openalex.org/W2503566978","doi":"https://doi.org/10.1200/jco.2016.34.2_suppl.419","title":"The utility of neutrophil-to-lymphocyte ratio in determining survival outcomes in patients treated with neoadjuvant chemotherapy and radical cystectomy for high-risk bladder cancer.","display_name":"The utility of neutrophil-to-lymphocyte ratio in determining survival outcomes in patients treated with neoadjuvant chemotherapy and radical cystectomy for high-risk bladder cancer.","publication_year":2016,"publication_date":"2016-01-10","ids":{"openalex":"https://openalex.org/W2503566978","doi":"https://doi.org/10.1200/jco.2016.34.2_suppl.419","mag":"2503566978"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2016.34.2_suppl.419","doi":"https://doi.org/10.1200/jco.2016.34.2_suppl.419","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.2_suppl.419","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021447034","display_name":"Chinedu Mmeje","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chinedu O. Mmeje","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082431868","display_name":"Austen D. Slade","orcid":"https://orcid.org/0000-0002-7579-5309","observed_orcids":["https://orcid.org/0000-0002-7579-5309"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Austen Slade","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Rebecca Slack","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rebecca Slack","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002421938","display_name":"Neema Navai","orcid":"https://orcid.org/0000-0001-8457-3786","observed_orcids":["https://orcid.org/0000-0001-8457-3786"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neema Navai","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069915515","display_name":"Jianjun Gao","orcid":"https://orcid.org/0000-0001-6138-4472","observed_orcids":["https://orcid.org/0000-0001-6138-4472"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jianjun Gao","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057758356","display_name":"Arlene Odelia Siefker-Radtke","orcid":"https://orcid.org/0000-0002-6328-9599","observed_orcids":["https://orcid.org/0000-0002-6328-9599"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Arlene O. Siefker-Radtke","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034005227","display_name":"Ashish M. Kamat","orcid":"https://orcid.org/0000-0003-3546-9928","observed_orcids":["https://orcid.org/0000-0003-3546-9928"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ashish M. Kamat","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002737792","display_name":"Colin P. Dinney","orcid":"https://orcid.org/0000-0002-8969-711X","observed_orcids":["https://orcid.org/0000-0002-8969-711X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Colin P. N. Dinney","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5054731898","display_name":"Jay Bakul Shah","orcid":"https://orcid.org/0000-0003-0339-0916","observed_orcids":["https://orcid.org/0000-0003-0339-0916","https://orcid.org/0000-0003-1139-8774"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jay Bakul Shah","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"34","issue":"2_suppl","first_page":"419","last_page":"419"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11355","display_name":"Inflammatory Biomarkers in Disease Prognosis","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11355","display_name":"Inflammatory Biomarkers in Disease Prognosis","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12626","display_name":"Cancer, Stress, Anesthesia, and Immune Response","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/neutrophil-to-lymphocyte-ratio","display_name":"neutrophil-to-lymphocyte ratio","score":0.9990000128746033},{"id":"https://openalex.org/keywords/high-risk-bladder-cancer","display_name":"high-risk bladder cancer","score":0.8299999833106995},{"id":"https://openalex.org/keywords/urothelial-carcinoma","display_name":"urothelial carcinoma","score":0.9240000247955322},{"id":"https://openalex.org/keywords/neoadjuvant-chemotherapy","display_name":"neoadjuvant chemotherapy","score":0.9919999837875366},{"id":"https://openalex.org/keywords/radical-cystectomy","display_name":"radical cystectomy","score":1.0},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.7749999761581421},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7279999852180481},{"id":"https://openalex.org/keywords/disease-specific-survival","display_name":"disease-specific survival","score":0.9980000257492065},{"id":"https://openalex.org/keywords/inflammatory-markers","display_name":"inflammatory markers","score":0.4230000078678131},{"id":"https://openalex.org/keywords/treatment-response-prediction","display_name":"treatment response prediction","score":0.3050000071525574},{"id":"https://openalex.org/keywords/recurrence-free-survival","display_name":"recurrence-free survival","score":0.3799999952316284}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9274760484695435},{"id":"https://openalex.org/C2775910329","wikidata":"https://www.wikidata.org/wiki/Q245995","display_name":"Cystectomy","level":4,"score":0.7940241098403931},{"id":"https://openalex.org/C2780352672","wikidata":"https://www.wikidata.org/wiki/Q504775","display_name":"Bladder cancer","level":3,"score":0.766575813293457},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6687841415405273},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.6148808002471924},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5751224756240845},{"id":"https://openalex.org/C2778963024","wikidata":"https://www.wikidata.org/wiki/Q17132454","display_name":"Neutrophil to lymphocyte ratio","level":3,"score":0.5747630596160889},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.49043747782707214},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.47943586111068726},{"id":"https://openalex.org/C144301174","wikidata":"https://www.wikidata.org/wiki/Q7893852","display_name":"Univariate analysis","level":3,"score":0.46472814679145813},{"id":"https://openalex.org/C2779399171","wikidata":"https://www.wikidata.org/wiki/Q1483951","display_name":"Malignancy","level":2,"score":0.4255119860172272},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3748885989189148},{"id":"https://openalex.org/C38180746","wikidata":"https://www.wikidata.org/wiki/Q1952580","display_name":"Multivariate analysis","level":2,"score":0.36679816246032715},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3580649793148041},{"id":"https://openalex.org/C2777761686","wikidata":"https://www.wikidata.org/wiki/Q715347","display_name":"Lymphocyte","level":2,"score":0.27728623151779175}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2016.34.2_suppl.419","doi":"https://doi.org/10.1200/jco.2016.34.2_suppl.419","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.2_suppl.419","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2602593037","https://openalex.org/W2600359837","https://openalex.org/W2028944115","https://openalex.org/W2602185078","https://openalex.org/W4380320588","https://openalex.org/W1989925694","https://openalex.org/W2296829825","https://openalex.org/W4206934214","https://openalex.org/W4393278810","https://openalex.org/W850103728"],"abstract_inverted_index":{"419":[0],"Background:":[1],"Pre-operative":[2],"neutrophil-to-lymphocyte":[3],"ratio":[4],"(NLR)":[5],"has":[6],"been":[7],"found":[8],"to":[9,33,108,135,220],"be":[10],"associated":[11,276],"with":[12,23,43,61,93,141,194,199,226,277,285,303],"adverse":[13],"pathological":[14],"results":[15],"and":[16,47,63,79,86,104,121,143,179,196,212,216,222,258,280,287],"poor":[17,278],"long-term":[18],"outcomes":[19],"in":[20,40,151,183,282,301],"patients":[21,41,59,92,147,225,283,302],"treated":[22,42,60,284],"radical":[24],"cystectomy":[25],"(RC)":[26],"for":[27,49,114,174,177,181,224,296],"urothelial":[28],"carcinoma":[29],"(UC).":[30],"We":[31,53,70,90,101,117,129,167],"aimed":[32],"evaluate":[34],"the":[35,55,81,110,126,137,191,235],"predictive":[36],"utility":[37],"of":[38,57,75,139,172,214,246],"NLR":[39,72,112,140,149,170,184,189,202,228,239,272],"neoadjuvant":[44],"chemotherapy":[45],"(NAC)":[46],"RC":[48,64,87,300],"high-risk":[50,304],"UC.":[51],"Methods:":[52],"reviewed":[54],"records":[56],"585":[58],"NAC":[62,76,85,286],"at":[65],"our":[66,152],"institution":[67],"from":[68],"2000-2013.":[69],"calculated":[71],"before":[73],"initiation":[74],"(pre-chemo":[77],"NLR)":[78],"during":[80],"recovery":[82],"window":[83],"between":[84],"(post-chemo":[88],"NLR)..":[89],"excluded":[91],"concomitant":[94],"infection,":[95],"blood":[96],"disorder,":[97],"or":[98],"second":[99],"malignancy.":[100],"used":[102,130],"univariate":[103],"multivariate":[105],"CART":[106],"models":[107],"determine":[109],"optimal":[111,169],"cut-off":[113],"survival":[115,123],"outcomes.":[116],"estimated":[118],"disease-specific":[119],"(DSS)":[120],"overall":[122],"(OS)":[124],"using":[125],"Kaplan-Meier":[127],"method.":[128],"Cox":[131],"proportional":[132],"hazards":[133],"regression":[134],"explore":[136],"association":[138,193],"DSS":[142,211,247,279],"OS.":[144],"Results:":[145],"584":[146],"had":[148,208],"information":[150],"cohort.":[153],"The":[154],"median":[155],"follow-up":[156],"among":[157],"survivors":[158],"was":[159,242],"4.9":[160,176,204,230,241,274],"years":[161],"(IQR":[162],"2.4":[163],"\u2013":[164,186],"8.8":[165],"years).":[166],"identified":[168],"cut-points":[171],"7.1":[173],"pre-chemo,":[175],"post-chemo,":[178],"1.9":[180],"change":[182],"[(post-chemo)":[185],"(pre-chemo)].":[187],"Post-chemo":[188],"showed":[190],"strongest":[192],"OS":[195,213,259,281],"DSS.":[197],"Patients":[198],"a":[200,209],"post-chemo":[201,238,271],"\u2265":[203,240,273],"(n":[205,231],"=":[206,232,249,261],"103)":[207],"5-yr":[210],"42%":[215],"33%":[217],"respectively,":[218],"compared":[219],"69%":[221],"58%":[223],"an":[227,243],"<":[229,255,267],"481).":[233],"In":[234],"multivariable":[236],"analysis,":[237],"independent":[244],"predictor":[245],"(HR":[248,260],"2.5":[250],"[95%":[251,263],"CI:1.8,":[252],"3.6]":[253],"p":[254,266],"0.001":[256],"),":[257],"2.1":[262],"CI:1.6,":[264],"2.8]":[265],"0.001).":[268],"Conclusions:":[269],"A":[270],"is":[275],"RC.":[288],"These":[289],"findings":[290],"may":[291],"help":[292],"guide":[293],"treatment":[294],"planning":[295],"adjuvant":[297],"therapy":[298],"following":[299],"clinically":[305],"localized":[306],"bladder":[307],"cancer.":[308]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2016-08-23T00:00:00"}